Form 4: Citius Oncology CEO Awarded Stock Options
SEC Form 4
Citius Oncology's CEO, Leonard L. Mazur, was granted stock options on December 12, 2024, as part of his compensation.
Summary
- Leonard L. Mazur, CEO of Citius Oncology, was granted 800,000 stock options with an exercise price of $1.07 on December 12, 2024.
- These options vest in three equal tranches on the one, two, and three-year anniversaries of the grant date, contingent on continuous service.
- Mazur also holds previously granted options for 3,700,000 shares with an exercise price of $2.15, which vest over three years from July 5, 2023.
Sentiment
Score: 7
Explanation: The document reflects a standard executive compensation practice, which is generally viewed positively as it aligns management and shareholder interests. There are no negative implications.
Positives
- The granting of stock options aligns the CEO's interests with those of the shareholders.
- The vesting schedule encourages long-term commitment from the CEO.
Risks
- The value of the options is dependent on the future performance of the company's stock price.
- If the stock price does not increase above the exercise price, the options may not be valuable to the CEO.
Future Outlook
The vesting of the options is contingent on the CEO's continuous service to the company.
Industry Context
Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with shareholder value creation.
Comparison to Industry Standards
- Stock option grants are a standard practice for incentivizing executives in the biotech sector, similar to companies like Amgen and Gilead Sciences.
- The vesting schedule of these options is typical, with a three-year vesting period being common in the industry.
- The exercise prices are set at a level that is intended to motivate the CEO to increase the company's share price.
Stakeholder Impact
- Shareholders may view the stock option grant positively as it incentivizes the CEO to increase the company's value.
- Employees may see this as a sign of the company's commitment to its leadership.
Key Dates
| Date | Description |
|---|---|
| 07/05/2023 | Start date for vesting of previously granted options. |
| 12/12/2024 | Date of grant for 800,000 stock options. |
| 12/16/2024 | Date of signature for the SEC filing. |
| 12/12/2034 | Expiration date for the newly granted stock options. |
Keywords
stock options, executive compensation, insider trading, CEO, Citius Oncology, CTOR, equity
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.